

## Siegfried affected by attack on its IT systems



**(SIX: SFZN) The Siegfried Group's IT network has become the target of a malware attack. The company immediately initiated extensive measures to ensure the safety of its employees and facilities at all times and to avert further damage. The root cause has been identified and the recovery of the systems has started.**

In the night to Friday, May 21, 2021, an attack with malware on Siegfried's IT network was discovered by internal monitoring systems. As an immediate measure, production was shut down at various sites, network connections were interrupted and all IT systems were subjected to an in-depth investigation, which is currently still ongoing. The safety of all employees and production facilities was guaranteed at all times. With the exception of the two sites in Spain, which operate on an isolated network, there will be varying degrees of production interruption at the other sites.

Cooperation of internal and external specialists for IT infrastructure and security is running smoothly and efficiently. In the meantime, the root cause has been identified and the recovery of the systems has started. This also includes the assessment by when the IT systems will be fully operational again.

## Contact

### Media

Peter A. Gehler  
Mobile +41 79 416 41 16

Siegfried Holding AG  
Untere Bruehlstrasse 4  
CH-4800 Zofingen

### Investor Relations

Dr. Reto Suter, CFO  
Mobile +41 76 355 39 52

---

## This media release on the web

[www.siegfried.ch/media-releases](http://www.siegfried.ch/media-releases)

---

## About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2020, the Siegfried group achieved sales of CHF 845.1 million and currently employs approximately 3'500 people at eleven sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.